BiotechTube

DBV712 + DBV712

Phase 3Active
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Allergy, Peanut

Conditions

Allergy, Peanut

Trial Timeline

Feb 21, 2023 → Oct 1, 2029

NCT ID
NCT05741476

About DBV712 + DBV712

DBV712 + DBV712 is a phase 3 stage product being developed by DBV Technologies for Allergy, Peanut. The current trial status is active. This product is registered under clinical trial identifier NCT05741476. Target conditions include Allergy, Peanut.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05741476Phase 3Active

Competing Products

20 competing products in Allergy, Peanut

See all competitors
ProductCompanyStageHype Score
ASP0892 Intradermal + ASP0892 Intramuscular + Placebo Intradermal + Placebo IntramuscularAstellas PharmaPhase 1
33
ASP0892 + PlaceboAstellas PharmaPhase 1
33
Cetirizine 10mg + Cetirizine 10 mg + Cetirizine 10 mgJohnson & JohnsonPhase 1
33
Cetirizine + CetirizineJohnson & JohnsonPhase 1
33
AcalabrutinibAstraZenecaPhase 2
52
OmalizumabNovartisPhase 1
33
ligelizumab + PlaceboNovartisPhase 3
77
remibrutinib + placeboNovartisPhase 2
52
Placebo + XolairNovartisApproved
85
QGE031 + PlaceboNovartisPhase 2
52
Ligelizumab 120 mg + Ligelizumab 240 mgNovartisPhase 3
77
Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral ImmunotherapyNovartisPhase 3
77
QGE031 + PlaceboNovartisPhase 1
33
OmalizumabNovartisApproved
85
Omalizumab InjectionRocheApproved
85
Fluticasone + FluticasonRochePre-clinical
23
Dupilumab + Placebo matching dupilumab + AR101SanofiPhase 2
51
Fexofenadine HCISanofiApproved
84
DupilumabSanofiPhase 2
51
Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PESanofiPhase 1
32

Other Products from DBV Technologies

Viaskin Peanut 250 mcg + PlaceboPhase 3
72
DBV712 250 mcgPhase 3
72
Part A Viaskin Peanut 250 mcg + Part A Viaskin Peanut 100 mcg + Part A Placebo + Part B Viaskin Peanut 250 mcg + Part B PlaceboPhase 3
72
Viaskin Peanut 250mcg + PlaceboPhase 3
72
Viaskin Peanut 250µgPhase 3
72